Equity Overview
Price & Market Data
Price: $2.46
Daily Change: -$0.0801 / 3.26%
Daily Range: $2.46 - $2.60
Market Cap: $239,378,623
Daily Volume: 1,285,531
Performance Metrics
1 Week: -5.00%
1 Month: 1.23%
3 Months: -9.85%
6 Months: 58.33%
1 Year: -47.45%
YTD: -31.20%
Company Details
Employees: 110
Sector: Health technology
Industry: Biotechnology
Country:
Details
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.